Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,794,432 shares of the company’s stock after selling 37,310 shares during the quarter. Bank of New York Mellon Corp’s holdings in Teva Pharmaceutical Industries were worth $54,048,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Norges Bank purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $1,098,060,000. Harel Insurance Investments & Financial Services Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 19.2% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after purchasing an additional 7,255,083 shares during the period. Wellington Management Group LLP increased its holdings in shares of Teva Pharmaceutical Industries by 39,228.4% in the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after purchasing an additional 6,878,304 shares during the period. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Teva Pharmaceutical Industries by 18.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares during the last quarter. Finally, Schroder Investment Management Group raised its stake in shares of Teva Pharmaceutical Industries by 261.1% during the fourth quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company’s stock worth $231,793,000 after purchasing an additional 5,370,253 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on TEVA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Friday, July 17th. Truist Financial upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Piper Sandler restated an “overweight” rating and issued a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.78.

Teva Pharmaceutical Industries Trading Up 3.3%

Shares of TEVA stock opened at $31.16 on Friday. The business’s fifty day moving average price is $33.36 and its 200 day moving average price is $32.69. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The firm has a market capitalization of $35.82 billion, a PE ratio of 23.43, a P/E/G ratio of 3.18 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The company had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.99 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the sale, the insider owned 80,760 shares of the company’s stock, valued at approximately $2,825,792.40. The trade was a 64.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Richard Daniell sold 30,000 shares of the company’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the transaction, the executive vice president owned 55,755 shares in the company, valued at $1,973,727. The trade was a 34.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 465,931 shares of company stock worth $16,332,989. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.